Syndicate content

Archive - Jul 17, 2020

Date

Three COVID-19 Clinical Trials of Regeneron’s Antibody Cocktail REGN-COV2 Move Forward at University of Wisconsin-Madison School of Medicine & Public Health

The University of Wisconsin (UW) School of Medicine and Public Health and UW Health will conduct three clinical trials to test a new treatment and preventative for COVID-19, in collaboration with Regeneron Pharmaceuticals. The school will use its companion health system UW Health as a trial site to evaluate an “antibody cocktail,” dubbed REGN-COV2, created by the Tarrytown, New York-based pharmaceutical company. To create REGN-COV2, Regeneron scientists selected virus-neutralizing antibodies produced from mice that have been genetically modified to simulate a human immune system, as well as antibodies identified from humans who have recovered from COVID-19, according to Regeneron. The experimental antibodies interact with the receptor binding domain (RBD) of the SARS-CoV-2 virus’s spike (S) protein and block viral interaction with human angiotensin-converting enzyme 2 (ACE2), which is the cell-surface protein the virus docks with during infection. The three trials include: an adaptive Phase 1, 2, and 3 randomized, double-blinded, placebo-controlled study to evaluate the safety and efficacy in hospitalized patients with COVID-19; an adaptive Phase 1, 2, and 3 randomized, double-blinded, placebo-controlled study to evaluate the safety and efficacy in non-hospitalized patients with COVID-19; and a Phase 3 randomized, double-blinded, placebo-controlled study to evaluate the ability of REGN-COV2 to prevent an infection of the virus that causes COVID-19 in people who have been exposed to someone in their household with the disease. UW Health is one of approximately 100 trial sites for REGN-COV2 in the United States. Recruitment will begin immediately with a goal of enrolling 30 to 50 people per trial at the UW Health site.

All of Us Research Program at University of Wisconsin-Madison Joins Fight Against COVID-19

Those who have enrolled in the All of Us Research Program at the University of Wisconsin‒Madison and UW Health (https://allofus.wisc.edu/), now have the potential to directly impact the national fight against the COVID-19 pandemic. The National Institutes of Health (NIH), which oversees the nationwide program, recently announced that it is leveraging its diverse All of Us participant base to seek new insights into COVID-19 through antibody testing, a survey on the pandemic’s mental and physical impacts, and analysis of electronic health record information provided by participants. UW‒Madison, which is part of a Wisconsin consortium that includes Gundersen Health System, Marshfield Clinic, and the Medical College of Wisconsin, has actively enrolled individuals in the Madison and Milwaukee areas since All of Us launched in May 2018. UW Health is a key partner for recruitment and enrollment efforts in Madison. “This is an exciting opportunity for our participants to have a direct impact on COVID-19 research, watching how their participation in this historic effort is truly making a difference,” said Elizabeth Burnside, MD, Co-Principal Investigator, All of Us at UW‒Madison, and a UW Health physician. “This focused initiative could be especially important for members of communities that are often under-represented in health research and who may question the overall and personal benefit of research participation.” To date, more than 271,000 people nationwide have participated in the All of Us Program and more than 50% of them represent racial and ethnic minorities.

ISEV 2020 Virtual Annual Meeting (July 20-22) Will Be Covered by BioQuick News

The International Society for Extracellular Vesicles (ISEV) Annual Meeting (ISEV 2020), Including Exosomes, is now VIRTUAL (July 20-22); and will be featuring over 600 discussions (Plenary Addresses, Panel Sessions, Featured Abstracts, Oral Abstract Talks, Poster Chats, & Education Sessions), including both live and on-demand presentations. The meeting program can viewed here (https://www.isev.org/mpage/2020Program) and registration can be done here (https://www.isev.org/mpage/2020Registration). As Philip Askenase, MD, eminent Yale Medical School Professor and 30-Year Chief of Allergy & Immunology at Yale, has said, "Exosomes are a sensational biological discovery and they seem to be involved in nearly all biological and clinical processes.” Please consider attending the virtual ISEV 2020 meeting to learn more about these fascinating and immensely important tiny particles. And if you can’t make the live sessions July 20-22, be aware that all meeting presentations and other materials will be available to all registrants until September 21. BioQuick News (http://www.bioquicknews.com) is covering the ISEV 2020 Virtual Annual Meeting and will be posting articles throughout the meeting, and also afterwards. BioQuick News is dedicated to the timely reporting of key life science & medicine advances from around the globe. Headquartered in Madison, Wisconsin, USA, BioQuick News is a wholly independent publication and presently has readers in over 160 countries. BioQuick also has a Japanese-language edition. BioQuick has received numerous awards for publishing excellence and was recently ranked among the “Best Biology Blogs on the Planet.” BioQuick currently offers over 5,500 fully accessible articles on major life science/medicine advances (including >300 stories on exosomes/EVs).